You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Sumatriptan - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sumatriptan and what is the scope of freedom to operate?

Sumatriptan is the generic ingredient in ten branded drugs marketed by Glaxosmithkline, Cipla, Florida, Lannett Co Inc, Padagis Israel, Tonix Meds, Meridian Medcl, Antares Pharma Inc, Baxter Hlthcare Corp, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hikma, Mylan Labs Ltd, Par Pharm, Par Sterile Products, Sandoz, Somerset, Steriscience, Sun Pharm, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Endo Ventures Ltd, Currax, Teva Branded Pharm, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs, and is included in forty-seven NDAs. There are thirty-nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sumatriptan has ninety-one patent family members in twenty-nine countries.

There are twenty-four drug master file entries for sumatriptan. Eight suppliers are listed for this compound. There are six tentative approvals for this compound.

Drug Prices for sumatriptan

See drug prices for sumatriptan

Drug Sales Revenue Trends for sumatriptan

See drug sales revenues for sumatriptan

Recent Clinical Trials for sumatriptan

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Radboud University Medical CenterPhase 2
Canisius-Wilhelmina HospitalPhase 2
Leiden University Medical CenterPhase 2

See all sumatriptan clinical trials

Generic filers with tentative approvals for SUMATRIPTAN
Applicant Application No. Strength Dosage Form
⤷  Try a Trial⤷  Try a TrialEQ 100MG BASETABLET;ORAL
⤷  Try a Trial⤷  Try a TrialEQ 50MG BASETABLET;ORAL
⤷  Try a Trial⤷  Try a TrialEQ 25MG BASETABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Medical Subject Heading (MeSH) Categories for sumatriptan

US Patents and Regulatory Information for sumatriptan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Mylan SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 077744-003 Aug 10, 2009 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline IMITREX sumatriptan succinate TABLET;ORAL 020132-003 Jun 1, 1995 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Watson Labs SUMATRIPTAN SUCCINATE sumatriptan succinate TABLET;ORAL 076933-003 Aug 10, 2009 AB RX No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Mylan Labs Ltd SUMATRIPTAN SUCCINATE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 203322-001 Apr 14, 2014 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for sumatriptan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-002 Aug 26, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-002 Aug 26, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-001 Aug 26, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-003 Aug 26, 1997 ⤷  Try a Trial ⤷  Try a Trial
Glaxosmithkline IMITREX sumatriptan SPRAY;NASAL 020626-001 Aug 26, 1997 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for sumatriptan

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Galpharm Healthcare Ltd. Sumatriptan Galpharm sumatriptan EMEA/H/C/002140
Refused yes no no 2012-02-09
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for sumatriptan

Country Patent Number Title Estimated Expiration
Russian Federation 2762725 Композиции, содержащие триптановые соединения (COMPOSITIONS CONTAINING TRIPTANE COMPOUNDS) ⤷  Try a Trial
New Zealand 593782 Compositions for drug administration comprising a triptan analog and an alkylsaccharide ⤷  Try a Trial
United Kingdom 2587934 Intranasal epinephrine formulations and methods for the treatment of disease ⤷  Try a Trial
South Korea 20220035512 비강내 에피네프린 제제 및 질환의 치료 방법 (INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE) ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2010075465 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.